CN107709315A - 布鲁顿酪氨酸激酶的抑制剂 - Google Patents
布鲁顿酪氨酸激酶的抑制剂 Download PDFInfo
- Publication number
- CN107709315A CN107709315A CN201680035113.2A CN201680035113A CN107709315A CN 107709315 A CN107709315 A CN 107709315A CN 201680035113 A CN201680035113 A CN 201680035113A CN 107709315 A CN107709315 A CN 107709315A
- Authority
- CN
- China
- Prior art keywords
- substituted
- unsubstituted
- compound
- piperidin
- phenylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CCC*(CC*=C)C(c(cc1)ccc1N)=* Chemical compound CCC*(CC*=C)C(c(cc1)ccc1N)=* 0.000 description 88
- FTPYSVDIRTUGME-UHFFFAOYSA-N CC(C(CC=C)(N)N)=C=C Chemical compound CC(C(CC=C)(N)N)=C=C FTPYSVDIRTUGME-UHFFFAOYSA-N 0.000 description 1
- WQDBBOLZIXTESN-ALCCZGGFSA-N CC(C)/C=N\N(C)C Chemical compound CC(C)/C=N\N(C)C WQDBBOLZIXTESN-ALCCZGGFSA-N 0.000 description 1
- WDLVETZNDRSMIC-UHFFFAOYSA-O CCC(C(C(C(C)N)=C(C)C(C)C1)NC(C)C)C1(C)[NH3+] Chemical compound CCC(C(C(C(C)N)=C(C)C(C)C1)NC(C)C)C1(C)[NH3+] WDLVETZNDRSMIC-UHFFFAOYSA-O 0.000 description 1
- VXVPXCCGALLHIT-UHFFFAOYSA-N CCC(C(CC1)CCC1C(N)=O)(C#C)SCC Chemical compound CCC(C(CC1)CCC1C(N)=O)(C#C)SCC VXVPXCCGALLHIT-UHFFFAOYSA-N 0.000 description 1
- YPEOWFVJEOFGOJ-SJORKVTESA-N CCCCC[C@H]([C@H](CNCC(C=C)=C)NC)[IH][I](C)CC Chemical compound CCCCC[C@H]([C@H](CNCC(C=C)=C)NC)[IH][I](C)CC YPEOWFVJEOFGOJ-SJORKVTESA-N 0.000 description 1
- NYNVSRRLZJWWRQ-UHFFFAOYSA-N CCN(CCC[IH]CC)C1C[IH]C1 Chemical compound CCN(CCC[IH]CC)C1C[IH]C1 NYNVSRRLZJWWRQ-UHFFFAOYSA-N 0.000 description 1
- JTPZTKBRUCILQD-UHFFFAOYSA-N CN(CCN1)C1=O Chemical compound CN(CCN1)C1=O JTPZTKBRUCILQD-UHFFFAOYSA-N 0.000 description 1
- PWMRYRMTALJVQM-UHFFFAOYSA-N CN1NCN=C1 Chemical compound CN1NCN=C1 PWMRYRMTALJVQM-UHFFFAOYSA-N 0.000 description 1
- OWCDZJYSRZYAOV-BFHBGLAWSA-N C[C@@H]1C(C(N(CN)C2)=CN=C2C(N)=O)=CCCCC1N Chemical compound C[C@@H]1C(C(N(CN)C2)=CN=C2C(N)=O)=CCCCC1N OWCDZJYSRZYAOV-BFHBGLAWSA-N 0.000 description 1
- KNKLEJZODYSNBI-SNVBAGLBSA-N Cc1n[s]c(Nc2nc(N[C@H](CCC3)CN3C(C=C)=O)nnc2C(N)=O)c1 Chemical compound Cc1n[s]c(Nc2nc(N[C@H](CCC3)CN3C(C=C)=O)nnc2C(N)=O)c1 KNKLEJZODYSNBI-SNVBAGLBSA-N 0.000 description 1
- TXGHXWMKUWXPQZ-UHFFFAOYSA-N Cc1nccnc1Nc1ccccc1 Chemical compound Cc1nccnc1Nc1ccccc1 TXGHXWMKUWXPQZ-UHFFFAOYSA-N 0.000 description 1
- LDYLUOIANHBKAZ-UHFFFAOYSA-N NC(c1n[n](CCC2)c2c1)=O Chemical compound NC(c1n[n](CCC2)c2c1)=O LDYLUOIANHBKAZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562169941P | 2015-06-02 | 2015-06-02 | |
| US201562169945P | 2015-06-02 | 2015-06-02 | |
| US201562169935P | 2015-06-02 | 2015-06-02 | |
| US62/169,941 | 2015-06-02 | ||
| US62/169,945 | 2015-06-02 | ||
| US62/169,935 | 2015-06-02 | ||
| US201562249336P | 2015-11-01 | 2015-11-01 | |
| US201562249338P | 2015-11-01 | 2015-11-01 | |
| US201562249340P | 2015-11-01 | 2015-11-01 | |
| US62/249,340 | 2015-11-01 | ||
| US62/249,336 | 2015-11-01 | ||
| US62/249,338 | 2015-11-01 | ||
| PCT/US2016/035489 WO2016196776A2 (en) | 2015-06-02 | 2016-06-02 | Inhibitors of bruton's tyrosine kinase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107709315A true CN107709315A (zh) | 2018-02-16 |
Family
ID=57441893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201680035113.2A Pending CN107709315A (zh) | 2015-06-02 | 2016-06-02 | 布鲁顿酪氨酸激酶的抑制剂 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20180305348A1 (https=) |
| EP (1) | EP3310776A4 (https=) |
| JP (1) | JP2018522823A (https=) |
| KR (1) | KR20180021740A (https=) |
| CN (1) | CN107709315A (https=) |
| AU (2) | AU2016270907B2 (https=) |
| BR (1) | BR112017025986A2 (https=) |
| CA (1) | CA2987054A1 (https=) |
| IL (1) | IL255831A (https=) |
| MA (1) | MA42623A (https=) |
| MX (1) | MX2017015574A (https=) |
| RU (1) | RU2017145650A (https=) |
| SG (1) | SG10201911523YA (https=) |
| WO (1) | WO2016196776A2 (https=) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021244505A1 (zh) * | 2020-06-01 | 2021-12-09 | 微境生物医药科技(上海)有限公司 | 新型吡嗪化合物 |
| CN115557933A (zh) * | 2021-07-01 | 2023-01-03 | 杭州和正医药有限公司 | 布鲁顿酪氨酸激酶及其突变体降解剂、组合物及应用 |
| CN116143757A (zh) * | 2021-11-22 | 2023-05-23 | 杭州和正医药有限公司 | 一种可降解btk激酶的多功能化合物、组合物及应用 |
| RU2857201C2 (ru) * | 2020-06-01 | 2026-02-27 | Виген Биомедисн Текнолоджи (Шанхай) Ко., Лтд. | Новое соединение пиразина |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2856248T3 (es) * | 2016-12-21 | 2021-09-27 | Acerta Pharma Bv | Inhibidores de imidazopirazina de la tirosina quinasa de Bruton |
| KR101956815B1 (ko) * | 2017-02-14 | 2019-03-12 | 한국화학연구원 | 트리아졸로피리다진 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물 |
| CN109384774B (zh) * | 2017-08-11 | 2023-02-17 | 中国科学院上海药物研究所 | 一类多取代的吡嗪/三嗪酰胺类化合物及其制备方法和应用 |
| CN108530450B (zh) * | 2018-05-03 | 2021-03-30 | 赖建智 | 具有egfr抑制活性的化合物、制备方法及其在疾病治疗中的应用 |
| KR102797697B1 (ko) | 2018-05-25 | 2025-04-22 | 에이2에이 파마수티칼스, 잉크. | 신종 항암제 후보로서, 매우 강력한 tacc3 억제제 |
| JP7600123B2 (ja) | 2018-10-15 | 2024-12-16 | ニューリックス セラピューティクス，インコーポレイテッド | ユビキチンプロテオソーム経路を介してｂｔｋを分解するための二官能性化合物 |
| AU2019364336B2 (en) | 2018-10-22 | 2023-11-16 | Alumis Inc. | TYK2 inhibitors and uses thereof |
| WO2020167518A1 (en) * | 2019-02-13 | 2020-08-20 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| US20220143049A1 (en) | 2019-03-21 | 2022-05-12 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| EP3953346A1 (en) | 2019-04-09 | 2022-02-16 | Nurix Therapeutics, Inc. | 3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus |
| EP3969447A1 (en) | 2019-05-17 | 2022-03-23 | Nurix Therapeutics, Inc. | Cyano cyclobutyl compounds for cbl-b inhibition and uses thereof |
| MX2021015675A (es) | 2019-06-26 | 2022-02-03 | Nurix Therapeutics Inc | Compuestos de bencil-triazol sustituidos para la inhibicion de cbl-b y otros usos de los mismos. |
| EP4034141A1 (en) | 2019-09-24 | 2022-08-03 | Nurix Therapeutics, Inc. | Cbl inhibitors and compositions for expansion of immune cells |
| EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| US11820781B2 (en) | 2019-12-04 | 2023-11-21 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2022071772A1 (ko) * | 2020-09-29 | 2022-04-07 | (주)메디톡스 | 단백질 키나제 저해제 및 그의 용도 |
| US12016860B2 (en) | 2021-04-08 | 2024-06-25 | Nurix Therapeutics, Inc. | Combination therapies with Cbl-b inhibitor compounds |
| KR20240005751A (ko) * | 2021-04-12 | 2024-01-12 | 에이2에이 파마수티칼스, 잉크. | 암 치료를 위한 조성물 및 방법 |
| AU2022379494A1 (en) | 2021-10-26 | 2024-05-30 | Nurix Therapeutics, Inc. | Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading btk |
| EP4499625A4 (en) | 2022-03-24 | 2026-03-18 | A2A Pharmaceuticals Inc | CANCER COMPOSITIONS AND TREATMENT METHODS |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013052394A1 (en) * | 2011-10-05 | 2013-04-11 | Merck Sharp & Dohme Corp. | 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors |
| WO2013078466A1 (en) * | 2011-11-23 | 2013-05-30 | Portola Pharmaceuticals, Inc. | Pyrazine kinase inhibitors |
| WO2014153280A1 (en) * | 2013-03-22 | 2014-09-25 | Merck Sharp & Dohme Corp. | 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors |
| US20140323463A1 (en) * | 2012-01-17 | 2014-10-30 | Astellas Pharma Inc. | Pyrazinecarboxamide compound |
| CN104159891A (zh) * | 2012-01-10 | 2014-11-19 | 霍夫曼-拉罗奇有限公司 | 哒嗪酰胺化合物和它们作为syk 抑制剂的用途 |
| US20140343038A1 (en) * | 2011-09-30 | 2014-11-20 | Taiho Pharmaceutical Co., Ltd. | 1,2,4-triazine-6-carboxamide derivative |
| CN104470363A (zh) * | 2012-06-22 | 2015-03-25 | 博尔托拉制药公司 | 1,2,4-三嗪-6-甲酰胺激酶抑制剂 |
| CN104602681A (zh) * | 2012-06-22 | 2015-05-06 | 博尔托拉制药公司 | 取代的吡啶酰胺激酶抑制剂 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5107900A (en) * | 1999-06-09 | 2000-12-28 | Yamanouchi Pharmaceutical Co., Ltd. | Novel heterocyclic carboxamide derivatives |
| JP4622047B2 (ja) * | 1999-06-09 | 2011-02-02 | アステラス製薬株式会社 | 新規なヘテロ環カルボキサミド誘導体 |
| JP2014005206A (ja) * | 2010-10-22 | 2014-01-16 | Astellas Pharma Inc | アリールアミノヘテロ環カルボキサミド化合物 |
| HK1217695A1 (zh) * | 2013-03-05 | 2017-01-20 | F. Hoffmann-La Roche Ag | 布鲁顿氏酪氨酸激酶抑制剂 |
| WO2015039613A1 (zh) * | 2013-09-18 | 2015-03-26 | 北京韩美药品有限公司 | 抑制btk和/或jak3激酶活性的化合物 |
| AU2014360446A1 (en) * | 2013-12-05 | 2016-06-09 | Pharmacyclics, Llc | Inhibitors of Bruton's tyrosine kinase |
-
2016
- 2016-06-02 BR BR112017025986A patent/BR112017025986A2/pt not_active IP Right Cessation
- 2016-06-02 US US15/579,142 patent/US20180305348A1/en not_active Abandoned
- 2016-06-02 KR KR1020177037849A patent/KR20180021740A/ko not_active Withdrawn
- 2016-06-02 MX MX2017015574A patent/MX2017015574A/es unknown
- 2016-06-02 CA CA2987054A patent/CA2987054A1/en not_active Abandoned
- 2016-06-02 AU AU2016270907A patent/AU2016270907B2/en not_active Ceased
- 2016-06-02 CN CN201680035113.2A patent/CN107709315A/zh active Pending
- 2016-06-02 RU RU2017145650A patent/RU2017145650A/ru not_active Application Discontinuation
- 2016-06-02 SG SG10201911523YA patent/SG10201911523YA/en unknown
- 2016-06-02 EP EP16804424.6A patent/EP3310776A4/en not_active Withdrawn
- 2016-06-02 MA MA042623A patent/MA42623A/fr unknown
- 2016-06-02 WO PCT/US2016/035489 patent/WO2016196776A2/en not_active Ceased
- 2016-06-02 JP JP2017560655A patent/JP2018522823A/ja active Pending
-
2017
- 2017-11-21 IL IL255831A patent/IL255831A/en unknown
-
2019
- 2019-07-17 US US16/514,544 patent/US20210070748A1/en not_active Abandoned
-
2020
- 2020-12-11 AU AU2020286332A patent/AU2020286332A1/en not_active Abandoned
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140343038A1 (en) * | 2011-09-30 | 2014-11-20 | Taiho Pharmaceutical Co., Ltd. | 1,2,4-triazine-6-carboxamide derivative |
| WO2013052394A1 (en) * | 2011-10-05 | 2013-04-11 | Merck Sharp & Dohme Corp. | 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors |
| WO2013078466A1 (en) * | 2011-11-23 | 2013-05-30 | Portola Pharmaceuticals, Inc. | Pyrazine kinase inhibitors |
| CN104159891A (zh) * | 2012-01-10 | 2014-11-19 | 霍夫曼-拉罗奇有限公司 | 哒嗪酰胺化合物和它们作为syk 抑制剂的用途 |
| US20140323463A1 (en) * | 2012-01-17 | 2014-10-30 | Astellas Pharma Inc. | Pyrazinecarboxamide compound |
| CN104470363A (zh) * | 2012-06-22 | 2015-03-25 | 博尔托拉制药公司 | 1,2,4-三嗪-6-甲酰胺激酶抑制剂 |
| CN104602681A (zh) * | 2012-06-22 | 2015-05-06 | 博尔托拉制药公司 | 取代的吡啶酰胺激酶抑制剂 |
| WO2014153280A1 (en) * | 2013-03-22 | 2014-09-25 | Merck Sharp & Dohme Corp. | 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors |
Non-Patent Citations (1)
| Title |
|---|
| J. MICHAEL ELLIS等: "Overcoming Mutagenicity and Ion Channel Activity: Optimization of Selective Spleen Tyrosine Kinase Inhibitors", 《JOURNAL OF MEDICINAL CHEMISTRY》 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021244505A1 (zh) * | 2020-06-01 | 2021-12-09 | 微境生物医药科技(上海)有限公司 | 新型吡嗪化合物 |
| CN115698000A (zh) * | 2020-06-01 | 2023-02-03 | 微境生物医药科技(上海)有限公司 | 新型吡嗪化合物 |
| RU2857201C2 (ru) * | 2020-06-01 | 2026-02-27 | Виген Биомедисн Текнолоджи (Шанхай) Ко., Лтд. | Новое соединение пиразина |
| US12600714B2 (en) | 2020-06-01 | 2026-04-14 | Wigen Biomedicine Technology (shanghai) Co., Ltd. | Substituted pyrazinecarboxamide compounds for treating diseases related to EGFR mutation |
| CN115557933A (zh) * | 2021-07-01 | 2023-01-03 | 杭州和正医药有限公司 | 布鲁顿酪氨酸激酶及其突变体降解剂、组合物及应用 |
| CN115557933B (zh) * | 2021-07-01 | 2024-08-16 | 杭州和正医药有限公司 | 布鲁顿酪氨酸激酶及其突变体降解剂、组合物及应用 |
| CN116143757A (zh) * | 2021-11-22 | 2023-05-23 | 杭州和正医药有限公司 | 一种可降解btk激酶的多功能化合物、组合物及应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3310776A2 (en) | 2018-04-25 |
| JP2018522823A (ja) | 2018-08-16 |
| AU2020286332A1 (en) | 2021-01-21 |
| RU2017145650A (ru) | 2019-07-15 |
| KR20180021740A (ko) | 2018-03-05 |
| IL255831A (en) | 2018-01-31 |
| EP3310776A4 (en) | 2019-01-16 |
| AU2016270907A1 (en) | 2017-12-07 |
| MA42623A (fr) | 2018-06-20 |
| WO2016196776A2 (en) | 2016-12-08 |
| RU2017145650A3 (https=) | 2019-11-22 |
| BR112017025986A2 (pt) | 2018-08-14 |
| AU2016270907B2 (en) | 2020-09-17 |
| CA2987054A1 (en) | 2016-12-08 |
| WO2016196776A3 (en) | 2017-01-05 |
| SG10201911523YA (en) | 2020-02-27 |
| MX2017015574A (es) | 2018-08-09 |
| US20180305348A1 (en) | 2018-10-25 |
| US20210070748A1 (en) | 2021-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107709315A (zh) | 布鲁顿酪氨酸激酶的抑制剂 | |
| AU2020203447B2 (en) | Tyrosine kinase inhibitors | |
| JP6689314B2 (ja) | ブルトン型チロシンキナーゼの阻害剤 | |
| US9580416B2 (en) | Inhibitors of Bruton's tyrosine kinase | |
| WO2023086341A1 (en) | Inhibitors of kras | |
| TWI522359B (zh) | 做爲激酶抑制劑之吡咯并嘧啶化合物 | |
| CN104640861B (zh) | 作为激酶抑制剂的嘌呤酮化合物 | |
| US20240409558A1 (en) | Irreversible inhibitors of kras | |
| TW201546061A (zh) | 布魯頓氏酪胺酸激酶抑制劑 | |
| EP3906029A1 (en) | Inhibitors of menin-mll interaction | |
| CN106999494A (zh) | 布鲁顿酪氨酸激酶的抑制剂 | |
| US20180194762A1 (en) | PYRAZOLO[3,4-b]PYRIDINE AND PYRROLO[2,3-b]PYRIDINE INHIBITORS OF BRUTON'S TYROSINE KINASE | |
| US20250353854A1 (en) | Fused pyrimidine compounds as inhibitors of menin | |
| WO2024249950A1 (en) | Fused pyrimidine compounds as inhibitors of menin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180216 |